Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Nu Skin's (NUS) Q3 Earnings Beat Estimates, Revenues Miss

Published 11/05/2019, 10:37 PM
Updated 07/09/2023, 06:31 AM

Nu Skin Enterprises, Inc. (NYSE:NUS) released third-quarter 2019 results, wherein earnings surpassed the Zacks Consensus Estimate while sales missed the same. Further, both top and bottom lines declined year on year. The quarterly performance reflects limited sales meetings in Mainland China.

Q3 Highlights

Nu Skin delivered quarterly earnings of 79 cents a share, which beat the Zacks Consensus Estimate of 76 cents. However, the bottom line tumbled almost 16% from the year-ago quarter’s reported figure.

Nu Skin Enterprises, Inc. Price, Consensus and EPS Surprise

Nu Skin Enterprises, Inc. price-consensus-eps-surprise-chart | Nu Skin Enterprises, Inc. Quote

Revenues of $589.9 million missed the Zacks Consensus Estimate of $631 million and declined 12.6% from the prior-year quarter’s level. The metric includes a negative impact of 2% (or approximately $12 million) from foreign currency fluctuations. Revenues in the quarter were hurt by a tough regulatory environment in Mainland China, primarily due to meeting restrictions.

Sales leaders were 61,090, down 16% year over year, with Mainland China accounting for the majority of the decline. In fact, sales leaders deteriorated in all regions.

Nevertheless, Nu Skin’s customer base expanded 4% to 1,206,697, primarily on growth in Mainland China along with improvement in the EMEA region.

Gross profit came in at $449.8 million, down 13.1% from the year-ago quarter’s figure. Gross margin contracted 50 basis points (bps) to 76.2%, owing to a higher percentage of manufacturing revenues. Nu Skin’s base business gross margin contracted 10 bps to 78.6%.

Selling expenses amounted to $231.9 million, which accounted for 39.3% of revenues compared with 40.2% in the year-ago quarter. Meanwhile, general and administrative expenses of $147.9 million accounted for 25.1% of revenues, up from 24.5% in the year-ago quarter

Operating income declined 13.4% to $69.9 million, primarily due to lower revenues. Operating margin shrank 10 bps to 11.8%.

Regional Results

Revenues declined across most regions, except Japan wherein sales improved 6% from the prior-year quarter’s level. The highest drop was witnessed in Mainland China, where the metric declined 23%. Further, revenues fell 11% in the Americas/Pacific, 12% in South Korea, 9% in Southeast Asia, 10% in Hong Kong/Taiwan and 17% in EMEA.

Other Financial Details

Nu Skin ended the quarter with cash and cash equivalents of $320 million, long-term debt of $341.7 million and stockholders' equity of $845.8 million.

In a separate press release, Nu Skin announced a quarterly dividend of 37 cents per share, payable on Dec 11, 2019, to shareholders of record as of Nov 29.

Guidance

Nu Skin focuses on product launches and anticipates introducing various products to the market in 2020. These include a reformulated Tru Face Essence Ultra as well as new Galvanic gels. Also, the company unveiled its plans to launch a daily-use beauty device, which is expected to be a robust business driver in the second half of 2020.

Nu Skin is making efforts to improve its business in Mainland China. In fact, the company is seeing sequential stability in sales leaders and overall business in the region. However, management believes that a complete revival in sales leader numbers may take a few quarters.

Management expects 2020 revenues of $2.41-$2.43 billion, including currency headwinds of nearly 4%. Further, earnings are projected in the range of $3.07-$3.14 per share, indicating a decline from $3.52 delivered in the prior year. The Zacks Consensus Estimate for earnings in 2019 is currently pegged at $3.26 per share.

For the fourth quarter, the company projects revenues of $570-$590 million, including adverse currency impacts of nearly 2%. Earnings are anticipated between 68 cents and 75 cents per share, including costs related to the LIVE event hosted in October. In the year-ago period, Nu Skin’s adjusted earnings came in at $1.05 per share. The Zacks Consensus Estimate for fourth-quarter earnings is currently pegged at 88 cents per share.

Price Performance

Shares of this Zacks Rank #3 (Hold) company have gained 15.8% in the past three months compared with the industry’s growth of 2.2%.

Don’t Miss These Cosmetic Stocks

e.l.f. Beauty, Inc. (NYSE:ELF) , with a Zacks Rank #1 (Strong Buy), has an impressive earnings surprise record. You can see the complete list of today’s Zacks #1 Rank stocks here.

Helen of Troy (NASDAQ:HELE) , with a Zacks Rank #2 (Buy), has a long-term earnings per share growth rate of 7.6%.

Avon Products (NYSE:AVP) , also with a Zacks Rank #2, has a long-term earnings per share growth rate of 7.5%.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Helen of Troy Limited (HELE): Free Stock Analysis Report

Avon Products, Inc. (AVP): Free Stock Analysis Report

Nu Skin Enterprises, Inc. (NUS): Free Stock Analysis Report

e.l.f. Beauty Inc. (ELF): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.